Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“Cure. A word we rarely use in patients with metastatic breast cancer, for good reasons. Yet, 25 years of targeting HER2 taught us that some HER2+ breast cancers, even when spread, can respond so well to anticancer treatment that never reappear.
Glad to contribute with an interview to this excellent article on the topic.”
More posts featuring CancerWorld.
